Skip to content

Artivion

US · AORT #3212 by market cap
21.26 +0.05 +0.24%
Live - 5344 symbols - heartbeat 36s ago · 2026-10-09 19:30

Valuation each multiple against its own 5-year range

P/B ratio 2.36 Cheap vs history 26th percentile
5-year average 3.13 · #60 of 125 in Medical Devices
P/E ratio -360.17 Cheap vs history 9th percentile
5-year average -77.66 · forward 274.50
P/S ratio 2.23 Cheap vs history 30th percentile
5-year average 2.80 · forward 2.04 · #59 of 136 in Medical Devices

Vs. peers Medical Devices

Company Market cap P/E (TTM) P/B Div yield
Artivion (AORT) 1.04B -354.33 2.33 0.00%
Abbott Laboratories (ABT) 172.35B 32.23 3.37 2.45%
Medtronic (MDT) 113.18B 21.79 2.25 3.22%
Stryker Corp (SYK) 106.38B 28.74 4.43 1.25%
Boston Scientific (BSX) 61.93B 17.30 2.48 0.00%
Edwards Lifesciences (EW) 49.12B 49.54 4.63 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value34.65 Economic moatNone UncertaintyHigh

Trading 63.0% below Morningstar's fair value estimate.

Fair value

Artivion Inc may seem undervalued at first glance, due to its considerable price decline over the past year. However, to account for the risk associated with a potential value trap, we have limited its rating to 3 stars. The stock currently trades at a 38% discount to our quantitative fair value estimate of $34.65 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The company's balance sheet bolsters our fair value estimate. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. For example, the firm's EBITDA/interest coverage ratio of 2.1 sits in the bottom 20% globally. Although the firm's ability to cover interest payments with EBITDA is limited, shares could sharply rebound if economic circumstances change or recent investments reduce fears of default. We believe this is a sign that shares could be cheap.

On a different note, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 2.4%, for example, sits in the bottom 45% compared with global peers. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-09 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Artivion discussion 0 comments

Add a comment